lactobacillus fermentum GM090 + lactobacillus paracasei GMNL-133

Lactobacillus fermentum GM090 + Lactobacillus paracasei GMNL-133 is a probiotic combination developed by **GenMont Biotech Incorporation** for the adjuvant treatment of atopic diseases, including atopic dermatitis (eczema) and asthma. Marketed under brand names such as **Innovall ATOP** and **Allerbio**, this biologic combination consists of two specific bacterial strains typically formulated at a concentration of 4 billion viable cells per dose. The mechanism of action involves modulating the gut-immune axis to suppress Th2-mediated allergic responses, evidenced by significant reductions in serum IgE and IL-4 levels, while simultaneously promoting regulatory T cell (Treg) activity and increasing levels of anti-inflammatory cytokines like TGF-beta and IFN-gamma. Clinical evidence from randomized, double-blind, placebo-controlled trials (e.g., NCT01635738) demonstrates that a 12-week administration significantly reduces SCORAD scores, improves quality of life, and decreases sensitivity to common allergens like mites, milk, and eggs in pediatric patients.

Brand names

Innovall ATOPAllerbio

Other names

Lactobacillus fermentum GM-090Lactobacillus paracasei GMNL-133LP + LF mixture